Quantum Cyber N.V. current report, 29 December 2025

Business Context and Reporting Period

This Form 8-K is filed by Mainz Biomed N.V. (trading symbol: MYNZ), a Dutch public limited liability company, with a report date of December 29, 2025. The filing addresses "Other Events" (Item 8.01) regarding the utilization of an At-The-Market (ATM) equity distribution agreement with Maxim Group LLC. The document was signed on February 10, 2026.

Key Financial Metrics

The filing details a specific equity financing event rather than providing comprehensive financial statements.

  • Transaction Type: Sale of Ordinary Shares under an ATM Sales Agreement.
  • Shares Sold: 1,735,194 Ordinary Shares.
  • Gross Proceeds: $2,152,822.40 (before commissions and expenses).
  • Sales Period: January 5, 2026, through January 23, 2026.
  • ATM Capacity Utilized: The specific prospectus supplement for $2,152,823 was fully utilized.
  • Remaining ATM Capacity: Available under the overall agreement, subject to market conditions.

Note: The filing text does not provide clear values for revenue, profit, cash flow, margins, debt, or liquidity outside of the specific proceeds from this transaction.

Material Changes

The primary material change is the completion of a specific tranche of the equity offering. The Company sold the full amount authorized under the December 29, 2025, Prospectus Supplement. This represents a change in the Company's capital structure through the issuance of new shares and an increase in cash assets via the gross proceeds received.

Guidance, Outlook, and Risks

Management Commentary: The Company confirmed that the Prospectus Supplement has been fully utilized. Future sales may continue under the remaining capacity of the overall ATM agreement, dependent on market conditions.

Risks and Contingencies: The filing includes standard legal disclaimers stating that the report does not constitute an offer to sell securities in jurisdictions where such an offer would be unlawful without registration. The ability to sell further shares is contingent upon market conditions.

Investor Verification Checklist

  • Verify the exact commission and expense amounts deducted from the $2,152,822.40 gross proceeds to determine net cash inflow.
  • Confirm the remaining aggregate maximum offering amount available under the original $10,000,000 ATM agreement.
  • Review the Company's most recent Form 6-K or 10-K to assess overall liquidity and cash burn rates relative to these new proceeds.
  • Check for any subsequent filings regarding further sales under the remaining ATM capacity.
Disclaimer:
This AI-generated summary by MetaQuotes is based on SEC filings and may contain errors. Verify important details against the original SEC filings.